Company: ACBM
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001640334-25-001347
Chunk: 3

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-08-05
Form: 10-Q
Item: Item 1
Chunk 3
---
 (10,143)  (10,143)                             Balance, June 30, 2024  -  $-   60,042,000  $60,042  $32,300,453  $(32,636,893) $(276,398)

The accompanying notes are an integral part of these unaudited financial statements. 

 6Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

(Unaudited)

  Six months ended    June 30,    2025  2024        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(25,863) $(21,395)Adjustments to reconcile net loss to net cash used in operating activities:        Imputed interest - related parties  3,315   2,011 Changes in operating assets and liabilities:        Prepaid expenses  (35,000)  1,250 Accounts payable and accrued expenses  (58,967)  (1,708)Net cash used in operating activities  (116,515)  (19,842)         CASH FLOWS FROM FINANCING ACTIVITIES        Advances from related parties  116,065   20,392 Net cash provided by financing activities  116,065   20,392          Net change in cash  (450)  550 Cash at beginning of period  476   376 Cash at end of period $26  $926          SUPPLEMENTAL CASH FLOW INFORMATION:        Cash paid for income taxes $-  $- Cash paid for interest $-  $- 

The accompanying notes are an integral part of these unaudited financial statements.

 7Table of Contents

ACRO BIOMEDICAL CO., LTD.

Notes to Financial Statements

(Unaudited)

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS Acro Biomedical Co., Ltd. (the “Company”) is a Nevada corporation incorporated on September 24, 2014 under the name Killer Waves Hawaii, Inc. On January 30, 2017, the Company’s corporate name was changed to Acro Biomedical Co., Ltd. The Company’s business is the sale of